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Abstract
Background: Few patients are reported with dementia with Lewy bodies before fifty years-old, which may partly
reflect the difficulty of accurate diagnosis in young population. We report the case of a 44-year-old male with
pathologically confirmed sporadic dementia with Lewy bodies, who did not fulfil the revised clinical criteria for
this disease.
Case presentation: We document this atypical case with clinical and cognitive evaluation, imaging, biochemistry,
genetics and pathology investigations. Creutzfeldt-Jakob disease was first suspected in this patient with no
previous medical history, who developed acute and rapid cognitive impairment, L-dopa-non-responsive parkinsonism,
and delusion. Positive 14–3–3 protein was initially detected in cerebrospinal fluid and until the late stages of
the disease. Severe atrophy with no diffusion hypersignal was found on structural MRI as well as an extensive
hypometabolism on 18F-FDG-PET, in comparison to age-matched healthy volunteers. Genetic investigation found
no alpha-synuclein gene mutation. The patient died within 5 years, and post-mortem examination found numerous
Lewy bodies and Lewy neurites consistent with pure Lewy body disease.
Conclusions: This comprehensively described case illustrates that dementia with Lewy bodies can occur in young
patients with atypical clinical presentation. Biochemistry and neuroimaging investigations can sometimes be insufficient
to allow accurate diagnostic. More specific markers to support such diagnosis are needed.
Keywords: Dementia with Lewy bodies, 14–3–3 protein, Diagnosis, Genetics, Imaging
Background
Dementia with Lewy bodies (DLB) is the second most
common form of neurodegenerative dementia in the
population over 65 years-old [1], with an age of onset
varying from 50 to 80 [2]. The prevalence of DLB in
younger patients remains unknown. The recent criteria
for diagnosis of probable DLB require progressive cog-
nitive decline, accompanied by two out of three core fea-
tures: fluctuating alertness, recurrent visual hallucinations
and spontaneous motor Parkinsonism [3]. Despite these
criteria, clinical diagnosis of DLB may be difficult, and
some cases may be misdiagnosed with other dementia
such as Creutzfeldt-Jakob disease (CJD) [4]. Indeed,
CJD cases may share clinical similarities with DLB such
as dementia, visual disturbances and abnormal move-
ments (parkinsonism, myoclonia, dystonia and chorea).
Nevertheless, the onset of the symptoms in CJD is usu-
ally acute while insidious in DLB. We report the case of
a 44 year-old patient with acute dementia, first mimick-
ing CJD, but proved to have DLB at autopsy. Clinical,
neuropsychological, imaging and biological investiga-
tions are reported.* Correspondence: ory.f@chu-toulouse.fr
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Case presentation
Clinical follow-up
– Month 0: A 44 year-old man, 12 years of education,
started complaining acutely of slowness and
sustained attention difficulties. He had neither
clinical comorbidities nor relevant familial history.
Within three weeks after the first complaints, his sta-
tus rapidly worsened and the patient needed help for
every daily life activities. He was hospitalized, and pre-
sented significant cognitive impairment and walking
difficulties related to marked parkinsonian syndrome.
Depression with suicidal ideation was reported. No
cerebellar features were observed. Neuropsychological
assessment showed marked cognitive slowness and im-
pairment of anterograde memory, mental calculation,
verbal fluency, praxies and mental flexibility (Table 1).
Electroencephalogram (EEG) showed slow cerebral ac-
tivity without any epileptic or pseudo periodic abnor-
malities. Tianeptine and ropinirole treatments were
introduced.
– Month 2: His condition worsened, and he was
hospitalized in the Department of Neurology, in
University Hospital, Toulouse, France. In the
Table 1 Clinical, neuropsychological and biological assessments for the patient
M0 M2 M7 M15 M27 M43
Neuropsychological assessment
Global cognitive state
MMSE 25 25 24 21 17 13
Speed processing
TMT part A, time (seconds) 133 157 144 193 NA NA
Short term memory
WAIS III digit span forward 4 5 5 5 3 NA
WAIS III digit span backward 3 3 2 3 2 NA
Executive functions
Phonemic verbal fluency: letter ‘p’ 12 1 6 10 NA NA
Semantic verbal fluency: ‘animal’ category 15 16 16 12 NA NA
FAB (/18) 12 12 12 10 6 2
TMT part B, time (seconds) 296 537 486 NA NA NA
TMT part B, mistakes 0 1 (help) 1
Anterograde verbal memory
FCSRT
sum of free recalls (/48) 19 18 27 22 8 NA
sum of free + cued recalls (/48) 42 47 46 45 NA NA
recognition (/48) 47 48 48 45 NA NA
delayed free recall (/16) 9 6 8 6 NA NA
delayed free + cued recall (/16) 14 14 16 15 NA NA
Anterograde visual memory
Rey complex figure, memory (/36) < centile 10 - - - NA NA
Language
DO80 (/80) - - 60 - NA NA
Visuoconstructive praxies
Rey complex figure, copy (/36) 25 12 13.5 - NA NA
EEG
Slow cerebral activity
No epileptic or
pseudo-periodic abnormalities
- PSWC discharges
during hyperpnea
unchanged - -
Cognitive domains are mentioned in bold characters. Abbreviations: M month, NA Not achievable by the patient, “-” not available, “help” the patient needed help
to achieve the test, MMSE Mini Mental State Evaluation, TMT Trail Making Test, FCSRT Free and Cued Selective Recall Reminding Test, FAB Frontal Assessment
Battery, EEG electroencephalogram, PSWC periodic sharp-wave complex
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absence of sustained stimulation, the patient
remained motionless and speechless, due to severe
apathy. Falls occurred frequently (about once a day),
due to altered postural reflexes. After marked
stimulation, it was noticed that the patient was
depressed but not melancholic or suicidal. Marked
symmetric and axial parkinsonian syndrome did
not improve after L-dopa challenge. Slight reflex
myoclonus was noticed in the upper limbs. Ocular
saccades were slow but not limited. Apraxia and
executive dysfunctions had worsened. Detection of
14–3–3 protein performed from cerebrospinal fluid
(CSF) sample by western-blot was positive, whereas
cytology and biochemistry were normal. Structural
cerebral MRI revealed fronto-temporal atrophy
on visual assessment of T1 sequence, with no
abnormality on diffusion weighted imaging (DWI).
Ropinirole, and tianeptine treatments were replaced
by citalopram, oxazepam and zopliclone.
– Month 6: Daily risperidone treatment was
introduced due to delusions of persecution and
rare visual hallucinations.
– Month 7: Parkinsonism did not deteriorate with
the addition of neuroleptic agents. Delusions and
hallucinations remained present, although less
prominent, and cognitive functions kept worsening.
Structural MRI was unchanged, and 18F-FDG-PET
visual assessment showed severe hypometabolism
in parietal regions.
– Month 10: The patient only experienced few
hallucinations without delusions. Risperidone
treatment was stopped but parkinsonian
symptoms had worsened: he had severe dysarthria
and was not able to walk without assistance
because of his instability.
The patient had to be institutionalized 12 months after
symptoms onset.
– Month 20: Axial parkinsonian symptoms had
worsened: he had difficulties swallowing, severe
dysarthria, freezing in narrow place and total loss
of postural reflexes. He was bed-ridden most of the
day. CSF 14–3–3 protein remained positive, while
total-tau (238 pg/mL) and Aβ42 (511 pg/ml) levels
were within the normal ranges (norm < 450 pg/mL
and > 500 pg/mL, respectively).
MRI showed moderate striatal, brainstem, and bilateral
fronto-temporo-parietal atrophy on visual assessment.
– Month 43: Parkinsonian symptoms were very severe,
and myoclonus more pronounced. Important
perseverations, imitations, and grasping were
reported. Speech was unintelligible. Detection of
14–3–3 protein in CSF was negative.
The patient died one year later, aged 49, after a total
duration of 55 months. Cerebral histopathological exam-
ination was performed.
Imaging analyses
Grey matter density was assessed in our patient from his
first T1 MRI sequence (Fig. 1a), and compared to the grey
matter density of a group of 30 age-matched healthy con-
trols (age = 44.9 ± 3.8) from the online database OASIS
(http://www.oasis-brains.org/), using a whole brain z-score
map. The 18F-FDG-PET scan from our patient (Fig. 1c)
was also compared to another group of 23 age-matched
healthy controls (age = 44.3 ± 9.4) using z-scores map (for
details on the control population and imaging processing
procedures, see Additional file 1). All z-scores below −2 or
above 2 were considered as significant.
The patient showed global bilateral decrease of grey
matter density affecting all cortical regions as well as
subcortical structures and cerebellum (Fig. 1b and
Additional file 2). Negative z-scores below −5 were
found in parietal, temporal, but also frontal and insular
cortices. Left hippocampus and bilateral thalami were
spared. No z-score > 2 was found.
Regarding 18F-FDG-PET, the patient showed wide-
spread significant bilateral hypometabolism, encompass-
ing all cerebral lobes, most predominant in the parietal
lobe (Fig. 1d and Additional file 2). Negative z-scores
below −8 were found in parietal and medial temporal re-
gions. No difference compared to controls was found in
the thalamus, orbitofrontal regions, or the posterior cin-
gulate. Hypermetabolism was found in the putamen.
Histopathology
Preliminary examination was carried out on hematoxylin-
eosin stained paraffin sections, completed by immunohis-
tochemistry with the following antibodies: anti-tau AT8
(Thermo Fisher Scientific, Illkirch, France), anti-amyloid-
beta A4 (Dako, Trappes, France), anti-alpha-synuclein
(Leica Biosystems, Newcastle, UK), and anti-prion protein
12 F10 (Spibio, Montigny Le Bretonneux, France). Macro-
scopic brain examination showed a marked palor of the
substantia nigra, while anti-alpha-synuclein immunohisto-
chemistry revealed numerous Lewy bodies and Lewy
neurites in the frontal and temporal cortices, hippocam-
pus, substantia nigra, locus cœruleus, as well as in the dor-
sal motor nucleus of the vagus, occipital and entorhinal
cortices, and more rarely in the thalamus, caudate nu-
cleus, putamen, and pallidum (Fig. 2). Spongiosis was ab-
sent and anti-prion protein immunohistochemistry was
negative. A few AT8-positive neurofibrillary tangles were
noticed in the hippocampus and the entorhinal cortex,
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whereas anti-amyloid-beta 4 staining revealed neither neo-
cortical deposits nor amyloid angiopathy.
Molecular genetics
SNCA gene (encoding the alpha-synuclein) mutations
were investigated using bidirectional Sanger sequencing
on an ABI 3730 automated sequencer (Applied Biosys-
tem) and SeqScape v2.6 software (Applied Biosystems),
and multiplex ligation-dependent probe amplification
(MLPA, MRC-Holland). PRNP gene (encoding the prion
protein) mutations were investigated using a previously
described protocol [5]. Neither missense mutations nor
Fig. 2 Post-mortem tissue staining. a and c Hematoxylin and eosin stained section of the frontal cortex (a) and the substantia nigra (b). Black
arrows point at Lewy bodies in pigmented neurons. Bar scale = 20 μm. b, d and e Immuno-histochemistry with anti-alpha synuclein showing
Lewy bodies in the frontal cortex (c), the substantia nigra (d) and the locus cœruleus (e)
Fig. 1 MRI and 18F-FDG-PET imaging. Patient’s MRI T1 sequence at M2 (a) and 18F-FDG–PETscan at M43 (c). Comparison between the patient and
(b) age-matched healthy controls (n = 30) for grey matter density, (d) age-matched healthy controls (n = 23) for 18F-FDG uptake. Patient’s cortical
atrophy below −2 standard deviations is displayed with a white to dark red scale. Patient’s hypometabolism below −2 standard deviations is
displayed with a light green to dark blue scale while hypermetabolism is displayed with an orange to yellow scale. R = Right side
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multiplications were found in the SNCA gene (alpha-sy-
nuclein), and no mutation was identified in the PRNP
gene (prion protein) either. The polymorphism at codon
129 was methionine-methionine.
Conclusions
We report the case of a young patient with confirmed
DLB that did not fulfil the revised clinical criteria [3] (see
Table 2). Global cognitive impairment was indeed acute
at onset, while progressive impairment is a mandatory
requirement for DLB diagnosis. Moreover, no fluctuat-
ing cognition was observed during follow-up, while
75 % of DLB patients experience such fluctuations, which
are a core feature of typical DLB [6]. Our patient also ex-
perienced slight visual hallucinations for one year, in a
context of severe paranoid delusion without neuroleptic
sensitivity, while delirium duration is usually short in DLB
[7]. Moreover, hallucinations may also occur in CJD [8].
The patient’s clinical presentation was similar to the
cognitive subtype of CJD described by Puoti et al. [9], with
Table 2 Early diagnostic profile of the case according to the revised criteria for the clinical diagnosis of dementia with Lewy bodies
(DLB) – adapted from McKeith et al., Neurology 2005 [3]
Dementia with Lewy
bodies
Creutzfeldt-Jakob disease Case reported
Central feature
Cognitive decline Progressive, insidious onset Acute or rapidly progressive Acute
Prominent or persistent memory impairment Not early: usually evident
with progression
Early Early
Prominent deficits of attention, executive
function, and visuospatial ability
Yes No (global dementia) No (global cognitive impairment)
Core features
Fluctuating cognition Yes No No
Recurrent visual hallucination Yes Yes No (mainly delirious with few
hallucinations)
Spontaneous features of parkinsonism Yes Yes Yes
Suggestive features
REM sleep behavior disorder Yes No Not reported by the wife
Severe neuroleptic sensitivity Yes No No
Low dopamine uptake in basal ganglia
on imaging
Yes Very rare
(one case reported [22])
Not performed
(the case was parkinsonian)
Supportive features
(Commonly present in DLB but not
proven to have diagnostic specificity)
Repeated falls and syncope Yes No Yes
Transient loss of consciousness Yes No No
Severe autonomic dysfunction Yes No No
Hallucinations in other modalities Yes No No
Systematized delusions Yes No Yes
Depression Yes Yes Yes
Relative preservation of medial temporal lobe
structures on MRI
Yes Yes Yes
Generalized low uptake on PET perfusion scan
with reduced occipital activity
Yes No Extensive hypometabolism
Prominent slow wave activity on EEG with
temporal lobe transient sharp waves
Yes No (biphasic and triphasic
periodic complex)
Slow but without temporal lobe
transient sharp waves
Other
Mean age of onset (years) 75 70 42
Mean duration (years) 7 0.5 5
Detection of 14.3.3 protein Rarely (3 cases reported) Yes Yes
Probable DLB Two core features or one core feature and one or more suggestive features, Possible DLB Up to one core feature and one or more suggestive features
Features for Creutzfeldt-Jakob disease are adapted from the MRI-CJD Consortium criteria for sporadic Creutzfeldt–Jakob disease [8]
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acute dementia, confusion and cortical visual disturbance,
extrapyramidal signs and myoclonus. Although MRI did
not show diffusion abnormalities, such clinical presenta-
tion and positive 14.3.3 protein detection were consistent
with CJD diagnosis [8]. Cases of DLB are reported in
neuropathological series of suspected CJD [4, 10–12]. But
in these series, patients are at least 60 years-old; symptom-
atic progression is rapid and leads to death within one to
two years. Despite an acute onset, our 44-year-old patient
showed a clinical progression and disease duration similar
to usual DLB [13], and no longer fulfilled the clinical cri-
teria for sporadic CJD disease [8] two years later.
Interestingly, patients suspected for CJD during life-
time but with confirmed DLB at autopsy often share
myoclonus, pyramidal and extrapyramidal symptoms
[10]. While fluctuating cognition and repeated falls are
rare, hallucinations and akinetic mutism are variable
among the series. When performed, 14–3–3 protein
detection is negative in most cases, except for Van
Everbroeck and colleagues who reported rare 14–3–3
protein positivity (less than 20 % of definite DLB) [14].
Of note, a recent study presented tau protein levels as
a better marker than 14–3–3 protein in the diagnosis
of CJD [15]. After 2 years of clinical evolution, CSF
total tau level was within the normal range, confirming
the hypothesis that our patient had no CJD.
As observed in our case, none of the previously re-
ported confirmed LBD patients with suspicion of CJD
had cerebellar symptoms, or hypersignal on MRI, but
most of them had diffuse cortical atrophy [10]. Regard-
ing our patient, comparison to a control population re-
vealed a wide bilateral atrophy involving all cortical
regions, as well as subcortical nuclei such as the puta-
men and the pallidum. Decrease of grey matter density
in the insula and the putamen has been recently re-
ported as a characteristic pattern of atrophy in patients
with DLB [16]. This pattern should also include lateral
temporal atrophy, but we reported a broader pattern of
atrophy, including other cortical regions. This extended
atrophy suggests an advanced stage of the pathology in
the patient’s brain, although the MRI used was per-
formed soon after clinical onset.
The patient also presented with widespread cortical
hypometabolism, sparing orbitofrontal regions as well as
posterior cingulate and thalamus. Interestingly, we found
bilateral hypermetabolism in the posterior part of the
putamen. To our knowledge, this is the first report of
striatal hypermetabolism in DLB [17]. Compensatory
mechanisms may explain this finding, but further inves-
tigations are required.
While mean age of onset for DLB is usually 75 years
old, ranging from 50 to 80, DLB can also be an uncom-
mon cause of dementia in young patients [18]. Few pa-
tients have been reported with DLB before 50 years-old
[2]. Most of them were reported in Japan [19], although
they did not fulfill the revised criteria for DLB, and may
not have had pure DLB [20]. Because our case was spor-
adic and because parkinsonism was the core clinical fea-
ture, molecular genetic analysis was limited to the alpha
synuclein and prion protein genes. However, other gen-
etic variations were also reported in DLB [21]. In this
case, the implication of these other genes is unlikely,
considering the pathological findings of Lewy bodies and
Lewy neurites without beta amyloid plaques or wide-
spread neurofibrillary tangles.
In summary, our case illustrates that DLB can occur in
young patients with an atypical and severe clinical pres-
entation, which can first be mistaken for CJD. Labora-
tory and neuroimaging investigations are useful to
exclude systemic and pharmacological causes of delirium
and cognitive impairment, but remain insufficient to
allow an accurate diagnostic of DLB, particularly in
young patients. Specific markers to support such diagno-
sis are needed.
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Additional file 1: Details on imaging methodological procedures.
(DOC 23 kb)
Additional file 2: Imaging regional quantification. The table displays
z-scores from quantitative comparison of 18F-FDG uptake and grey
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